DPP-4
Also known as: Dipeptidyl Peptidase-4, DPP-IV, CD26
DPP-4 is Dipeptidyl Peptidase-4, an enzyme that rapidly breaks down incretin hormones like GLP-1 and GIP. DPP-4 is responsible for the very short half-life of natural GLP-1. Modern GLP-1 receptor agonists are designed to resist DPP-4 degradation, while DPP-4 inhibitors are a class of diabetes medications.
Last updated: January 21, 2026
How DPP-4 Works
DPP-4 is an enzyme that:
- Recognizes specific sequences - Targets peptides with alanine or proline in position 2
- Cleaves the peptide - Removes two amino acids from the N-terminus
- Inactivates the hormone - Cleaved peptide loses biological activity
- Rapid process - GLP-1 half-life is just 1-2 minutes due to DPP-4
DPP-4 Substrates
DPP-4 affects multiple peptides:
| Peptide | Effect of DPP-4 | Clinical Relevance |
|---|---|---|
| GLP-1 | Inactivates | Major target for diabetes therapy |
| GIP | Inactivates | Affects incretin effect |
| NPY | Modifies activity | Appetite regulation |
| PYY | Inactivates | Satiety signaling |
| SDF-1 | Inactivates | Stem cell homing |
DPP-4 in Peptide Design
Understanding DPP-4 has driven peptide medication development:
Problem with Natural GLP-1
- Half-life: 1-2 minutes
- Therapeutic use impossible
- Would require continuous infusion
Solutions
DPP-4 Resistant Peptides:
- Semaglutide: Amino acid substitution at position 8 (Aib)
- Liraglutide: Fatty acid attachment provides protection
- Exenatide: Natural sequence from Gila monster resistant to DPP-4
DPP-4 Inhibitors (Gliptins):
- Block the enzyme itself
- Extend natural GLP-1 action
- Oral medications (sitagliptin, saxagliptin, linagliptin)
DPP-4 Inhibitors vs GLP-1 Agonists
| Feature | DPP-4 Inhibitors | GLP-1 Agonists |
|---|---|---|
| Mechanism | Block enzyme | Activate receptor |
| GLP-1 levels | 2-3x natural | Pharmacological (supraphysiological) |
| Administration | Oral | Mostly injection |
| Weight effect | Neutral | Weight loss |
| Potency | Moderate | Strong |
DPP-4 Beyond Diabetes
DPP-4 has roles beyond incretin metabolism:
- Immune function - Also known as CD26, expressed on immune cells
- Cancer biology - May affect tumor behavior
- Inflammation - Processes various cytokines and chemokines
Designing DPP-4 Resistant Peptides
Researchers use several strategies:
- Amino acid substitution - Replace susceptible position 2 amino acid
- Chemical modifications - Add protective groups
- Cyclization - Create cyclic structures resistant to cleavage
- Albumin binding - Fatty acids create steric protection
Frequently Asked Questions
Why does natural GLP-1 have such a short half-life?
Natural GLP-1 is rapidly degraded by DPP-4, which is present throughout the body (blood, endothelium, tissues). This limits the duration of the incretin effect after eating. The body produces more GLP-1 to compensate, but therapeutic use requires modifications.
Are DPP-4 inhibitors better than GLP-1 agonists?
Neither is universally better—they have different profiles. DPP-4 inhibitors are oral and well-tolerated but produce modest effects. GLP-1 agonists are more potent for glucose control and cause weight loss but require injection. Choice depends on individual patient needs.
Can you take both DPP-4 inhibitors and GLP-1 agonists?
Generally no. Combining them offers little benefit since GLP-1 agonists provide supraphysiological receptor activation that doesn’t depend on natural GLP-1 levels. The combination isn’t harmful but is redundant and not typically recommended.
Related Peptides
Related Terms
Disclaimer: This glossary entry is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for medical questions.